Stock Research: Sun Pharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Sun Pharmaceuticals

NSEI:SUNPHARMA INE044A01036
60
  • Value
    66
  • Growth
    23
  • Safety
    Safety
    41
  • Combined
    31
  • Sentiment
    82
  • 360° View
    360° View
    60
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Sun Pharmaceutical Industries Limited is a specialty generic pharmaceutical company. It operates in the specialty, generics, and consumer healthcare product industries. The company operates globally, with a focus on dermatology, ophthalmology, and onco-dermatology products. In the last fiscal year, the company had a market cap of $47,477 million, profits of $4,726 million, and revenue of $6,153 million with 43,000 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 60 (better than 60% compared with alternatives), overall professional sentiment and financial characteristics for the stock Sun Pharmaceuticals are above average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Sun Pharmaceuticals. The consolidated Sentiment Rank has a good rank of 82, which means that professional investors are more optimistic about the stock than for 82% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 66 or better than 66% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 41, meaning that the share price of Sun Pharmaceuticals is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 23. ...read more

more
Index
BSE Sensex
Good Governace Growth Markets
CNX Nifty 50
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
41 33 41 53
Growth
23 81 61 53
Safety
Safety
66 61 43 61
Sentiment
82 97 96 58
360° View
360° View
60 89 82 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
81 64 91 74
Opinions Change
49 75 49 52
Pro Holdings
n/a 90 85 16
Market Pulse
55 96 75 65
Sentiment
82 97 96 58
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
41 33 41 53
Growth
23 81 61 53
Safety Safety
66 61 43 61
Combined
31 73 43 63
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
40 40 46 50
Price vs. Earnings (P/E)
31 19 34 46
Price vs. Book (P/B)
45 37 45 56
Dividend Yield
57 48 43 46
Value
41 33 41 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
52 56 49 37
Profit Growth
28 57 42 16
Capital Growth
10 80 67 70
Stock Returns
51 75 63 75
Growth
23 81 61 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
71 62 50 62
Refinancing
53 40 48 58
Liquidity
68 84 64 61
Safety Safety
66 61 43 61

Similar Stocks

Discover high‑ranked alternatives to Sun Pharmaceuticals and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

NMDC

BSE:526371
Country: India
Industry: Steel
Size: Medium
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.